Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey. Show more

Location: Perryville III Building, Hampton, NJ, 08827, United States | Website: https://www.celldex.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.521B

52 Wk Range

$14.40 - $47.00

Previous Close

$22.68

Open

$22.64

Volume

808,270

Day Range

$22.50 - $23.55

Enterprise Value

681.3M

Cash

673.3M

Avg Qtr Burn

-42.88M

Insider Ownership

0.32%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Barzolvolimab (CDX-0159) Details
Chronic inducible urticaria

Phase 3

Initiation

Barzolvolimab (CDX-0159) (KIT receptor) Details
Prurigo nodularis, Skin disease/disorder

Phase 2

Data readout

Phase 2

Data readout

Barzolvolimab (CDX-0159) Details
Eosinophilic esophagitis (EoE)

Phase 2

Data readout

CDX-585 Details
Solid tumor/s, Cancer

Phase 1

Data readout

CDX-622 Details
Inflammatory disease

Phase 1

Data readout

Failed

Discontinued

CDX-1140 (CD40 agonist) Details
Solid tumor/s, Cancer, Diffuse large B cell lymphoma

Failed

Discontinued